Damora Therapeutics, Inc.
DMRANASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $1.29B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $4.95$38.33
- Volume (live)
- -
- Avg. volume (3M)
- 700.50K
Damora Therapeutics (DMRA) Stock Price & Financial Analysis
Damora Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $20.46 - $21.53 |
|---|---|
| 52-Week High | $38.33 |
| 52-Week Low | $4.95 |
| Open | $21.40 |
| Volume (last close) | 359.78K |
| Average Volume (3M) | 700.50K |
| 50-Day MA | $25.05 |
|---|---|
| 200-Day MA | $25.67 |
| 1-Year Change | +161.88% |
| Market Cap | 1.29B |
|---|---|
| Shares Outstanding | 61.12M |
| Price to Book (P/B) | 2.50 |
| EV/EBITDA | -2.94 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Damora Therapeutics at a Glance
As of the Oct 23, 2026 close, Damora Therapeutics (DMRA) has a market capitalization of $1.29B.
As of its latest reported balance sheet, it holds $540.51M in cash and securities against $0.00 of debt, a net cash position of $540.51M.
Damora Therapeutics does not currently pay a dividend.
The share price is up 161.9% over the past year. At $21.09 (the Oct 23, 2026 close) it sits within its 52-week range of $4.95 to $38.33, below its 200-day moving average of $25.67.
Based on 7 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $46.67, 121.3% above the Oct 23, 2026 close.
Frequently Asked Questions About Damora Therapeutics
What is the current stock price for DMRA?
As of the Oct 23, 2026 close, DMRA stock trades at $21.09. The 52-week range is $4.95–$38.33, with a day range of $20.46–$21.53.
What is the P/E ratio for DMRA?
The P/E ratio (Price-to-Earnings) for DMRA is shown in the Key Statistics section. This valuation metric helps compare Damora Therapeutics, Inc. to industry peers.
Does DMRA pay dividends?
Damora Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for DMRA?
Based on ratings from 7 professional analysts over the last 90 days, the consensus for DMRA is Buy. The average 12-month price target is $46.67, a 121.3% upside from the Oct 23, 2026 close of $21.09.
What is the market cap of DMRA?
As of the Oct 23, 2026 close, Damora Therapeutics's market capitalization is $1.29B, classifying it as a small-cap company. Damora Therapeutics operates in the Healthcare sector within the Biotechnology industry.